BC Week In Review | Jan 16, 2012
Clinical News

CMV-IGIV: Phase III start

This month, NIH will begin a double-blind, placebo-controlled U.S. Phase III trial to evaluate IV 100 mg/kg CytoGam in about 800 pregnant women. The trial will screen more than 150,000 pregnant women over 4 years...
BC Week In Review | Jan 1, 2007
Company News

CSL, MedImmune Inc. deal

CSL's ZLB Behring LLC subsidiary completed its acquisition of MEDI's CytoGam cytomegalovirus (CMV) immune globulin to prevent CMV disease associated with transplantation (see BioCentury, Nov. 13, 2006). MEDI will receive $50 million up front and...
BC Week In Review | Nov 13, 2006
Company News

CSL, MedImmune Inc. deal

CSL will acquire MEDI's CytoGam cytomegalovirus immune globulin to prevent cytomegalovirus (CMV) disease associated with transplantation. MEDI, which said CytoGam no longer fits into its core area of focus, will receive $50 million up front...
BC Extra | Nov 9, 2006
Company News

MedImmune to divest CytoGam

CSL (ASX:CSL) will acquire MEDI's CytoGam cytomegalovirus immune globulin to prevent cytomegalovirus (CMV) disease associated with transplantation. MEDI, which said CytoGam no longer fits into its core area of focus, will receive $50 million up...
BioCentury | Sep 3, 2002
Strategy

Back to School: The Sweet Spot

Enough of gloom and doom. This year's Back to School issue leaves aside all thoughts of the stock market and instead focuses on what in the end is really important: strategies for building very small...
BioCentury | Sep 3, 2002
Strategy

MedImmune's pipeline

MedImmune's pipeline Product Indication Status Synagis palivizumab RSV Mkt Ethyol amifostine Chemoprotection Mkt CytoGam CMV immune globulin CMV Mkt RespiGam RSV immune globulin RSV Mkt Neutrexin trimetrexate Pneumocystis carinii pneumonia Mkt FluMist intranasal influenza vaccine...
BioCentury | Dec 10, 2001
Strategy

MEDI-AVIR pipeline

MEDI-AVIR pipeline Product Indication Status Company Partner Ethyol Reduce chemotherapy toxicity in ovarian, NSCL and head and neck cancers Marketed MEDI Ethyol Prevent xerostomia following radiation therapy Marketed; Phase II MEDI NeuTrexin Pneumocystis carinii pneumonia...
BioCentury | Dec 10, 2001
Strategy

MEDI-AVIR pipeline

MEDI-AVIR pipeline Product Indication Status Company Partner Ethyol Reduce chemotherapy toxicity in ovarian, NSCL and head and neck cancers Marketed MEDI Ethyol Prevent xerostomia following radiation therapy Marketed; Phase II MEDI NeuTrexin Pneumocystis carinii pneumonia...
BioCentury | Jun 11, 2001
Finance

Testing demand

It would be easy to look at the nearly $1 billion of biotech paper that Wall Street priced last week and declare that the biotech window has been thrown open. But a closer look at...
BioCentury | Nov 8, 1999
Tools & Techniques

Approved protein & antibody therapeutics

Approved protein & antibody therapeutics Company Product Indication Year first approved Alpha Therapeutic Albutein albumin Hypovolemic shock, hemodialysis and cardiopulmonary bypass 1986 Alphanate Factor VIII AlphaNine Factor IX Venoglobulin-S IgG Hemophilia A Hemophilia B Immunodeficiencies...
Items per page:
1 - 10 of 37